Apogee receives grant from the Food and Drug Administration

Apogee is pleased to announce receipt of a grant award in the amount of $400,000 from the Office of Orphan Products Development of the FDA.  This funding will partially support the ongoing phase I clinical trial of its lead compound, ABC294640, in patients with advanced solid tumors, with emphasis on pancreatic cancer patients.  ABC294640 is a first-in-class inhibitor of the enzyme sphingosine kinase-2, and has anti-proliferative and anti-inflammatory activity in several preclinical animal models.  Dr. Charles Smith, President and CEO of Apogee, stated “We are pleased to receive the support of the Orphan Drug Office at the FDA as we go after pancreatic cancer in the clinic.”  Apogee was eligible for this competitive grant because ABC294640 has received Orphan Drug designation from the FDA for the potential treatment of advanced pancreatic cancer.

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE